To further test the therapeutic effects of gilteritinib in vivo, we evaluated its anti-leukemic efficacy using two xenograft models of ZNF384-r ALL (TCZ and JIH5). The gene discussed is ZNF384; the disease is acute lymphoblastic leukemia.